Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer.
Carcinoembryonic antigen (CEA)
Cytokeratin 19 fragment
chemotherapy
non-small cell lung cancer (NSCLC)
prognostic factor
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
2
8
2019
pubmed:
2
8
2019
medline:
2
8
2019
Statut:
ppublish
Résumé
It is unclear whether changes in serum tumor marker expression post-treatment are of prognostic value. We investigated the associations between changes in serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21-1) after first-line treatment and overall survival (OS) in non-small cell lung cancer (NSCLC). Advanced NSCLC patients (April 2010 to December 2015) with elevated serum CEA or CYFRA 21-1 were included. The associations between tumor marker changes after treatment initiation and OS were analyzed. Ninety-six and 55 patients were CEA- and CYFRA 21-1-positive, respectively. The serum CEA response at 4 months and CYFRA 21-1 responses at 1 and 4 months were significantly associated with OS in the univariate analyses (P=0.025, P=0.016 and P<0.001, respectively). Moreover, in the multivariate analyses, serum CYFRA 21-1 response at 4 months was significantly associated with improved OS (P=0.038). In NSCLC patients, serum CEA and CYFRA 21-1 responses after treatment initiation may predict longer OS.
Sections du résumé
BACKGROUND
BACKGROUND
It is unclear whether changes in serum tumor marker expression post-treatment are of prognostic value. We investigated the associations between changes in serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21-1) after first-line treatment and overall survival (OS) in non-small cell lung cancer (NSCLC).
METHODS
METHODS
Advanced NSCLC patients (April 2010 to December 2015) with elevated serum CEA or CYFRA 21-1 were included. The associations between tumor marker changes after treatment initiation and OS were analyzed.
RESULTS
RESULTS
Ninety-six and 55 patients were CEA- and CYFRA 21-1-positive, respectively. The serum CEA response at 4 months and CYFRA 21-1 responses at 1 and 4 months were significantly associated with OS in the univariate analyses (P=0.025, P=0.016 and P<0.001, respectively). Moreover, in the multivariate analyses, serum CYFRA 21-1 response at 4 months was significantly associated with improved OS (P=0.038).
CONCLUSIONS
CONCLUSIONS
In NSCLC patients, serum CEA and CYFRA 21-1 responses after treatment initiation may predict longer OS.
Identifiants
pubmed: 31367536
doi: 10.21037/tlcr.2019.06.08
pii: tlcr-08-03-227
pmc: PMC6626854
doi:
Types de publication
Journal Article
Langues
eng
Pagination
227-234Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Chest. 1999 Sep;116(3):697-703
pubmed: 10492274
Anticancer Res. 1999 Jul-Aug;19(4C):3613-8
pubmed: 10629660
Lung Cancer. 2000 Mar;27(3):159-67
pubmed: 10699689
Respiration. 2002;69(1):25-9
pubmed: 11844959
Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):357-64
pubmed: 12243808
Lung Cancer. 2007 Aug;57(2):213-21
pubmed: 17449138
J Thorac Oncol. 2007 May;2(5):402-7
pubmed: 17473655
J Thorac Oncol. 2007 Jul;2(7):632-7
pubmed: 17607119
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Tumour Biol. 2009;30(3):121-9
pubmed: 19506400
J Thorac Oncol. 2010 Jan;5(1):3-9
pubmed: 19884856
Exp Ther Med. 2013 Aug;6(2):355-360
pubmed: 24137188
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
Tumour Biol. 2014 Oct;35(10):10105-10
pubmed: 25023403
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
Lung Cancer. 2015 Feb;87(2):193-200
pubmed: 25564398
Cancer Treat Res. 2016;170:47-75
pubmed: 27535389
Oncotarget. 2017 Jan 17;8(3):4043-4050
pubmed: 28008142
Br J Cancer. 1995 Jul;72(1):170-3
pubmed: 7541234
JAMA. 1993 Aug 25;270(8):943-7
pubmed: 8141873
Br J Cancer. 1996 Oct;74(7):1126-31
pubmed: 8855986
Anticancer Res. 1998 Jan-Feb;18(1B):631-4
pubmed: 9584045